Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
Introduction: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and c...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2022-11-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.36401/JIPO-22-14 |
| _version_ | 1797979984650829824 |
|---|---|
| author | Anam A. Mazharuddin Andrew T. Whyte Dan S. Gombos Nimisha Patel Azadeh Razmandi Amina L. Chaudhry Nagham S. Al-Zubidi |
| author_facet | Anam A. Mazharuddin Andrew T. Whyte Dan S. Gombos Nimisha Patel Azadeh Razmandi Amina L. Chaudhry Nagham S. Al-Zubidi |
| author_sort | Anam A. Mazharuddin |
| collection | DOAJ |
| description | Introduction: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and clinical outcomes of ocular irAEs. Methods: In this retrospective, observational case series, we reviewed the medical records of 1280 patients at a large US tertiary cancer center between 2010 and 2020. Results: We identified 130 patients who presented with ocular irAEs (10%) with 69 males (53%) and 61 females (47%). The mean time to toxicity was 6.1 months. Adverse events include corneal toxicity (31%), neuro-ophthalmic (14%), uveitis and scleritis (13%), retinopathy (13%), periocular disorders (11%), and others. IrAEs occurred most frequently with nivolumab (26%). Most ocular irAEs were treated with topical therapy. Advanced cases required systemic corticosteroids and even cessation of ICIs. Conclusion: Our cohort is a large case series highlighting the increased potential of ocular toxicity associated with ICIs. Prompt recognition and management of ocular irAEs can minimize their effect. |
| first_indexed | 2024-04-11T05:47:20Z |
| format | Article |
| id | doaj.art-f781b5aa35b64598bbfb198113e72862 |
| institution | Directory Open Access Journal |
| issn | 2666-2345 2590-017X |
| language | English |
| last_indexed | 2024-04-11T05:47:20Z |
| publishDate | 2022-11-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj.art-f781b5aa35b64598bbfb198113e728622022-12-22T04:42:12ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2022-11-019810410.36401/JIPO-22-14i2590-017X-5-4-98Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer CenterAnam A. Mazharuddin0Andrew T. Whyte1Dan S. Gombos2Nimisha Patel3Azadeh Razmandi4Amina L. Chaudhry5Nagham S. Al-Zubidi61 Department of Ophthalmology, University of Texas Medical Branch, Galveston, TX, USA2 Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA2 Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA2 Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA2 Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA2 Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA2 Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAIntroduction: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and clinical outcomes of ocular irAEs. Methods: In this retrospective, observational case series, we reviewed the medical records of 1280 patients at a large US tertiary cancer center between 2010 and 2020. Results: We identified 130 patients who presented with ocular irAEs (10%) with 69 males (53%) and 61 females (47%). The mean time to toxicity was 6.1 months. Adverse events include corneal toxicity (31%), neuro-ophthalmic (14%), uveitis and scleritis (13%), retinopathy (13%), periocular disorders (11%), and others. IrAEs occurred most frequently with nivolumab (26%). Most ocular irAEs were treated with topical therapy. Advanced cases required systemic corticosteroids and even cessation of ICIs. Conclusion: Our cohort is a large case series highlighting the increased potential of ocular toxicity associated with ICIs. Prompt recognition and management of ocular irAEs can minimize their effect.https://theijpt.org/doi/pdf/10.36401/JIPO-22-14immune checkpoint inhibitorsocular immune-related adverse eventsnivolumabocular toxicityimmunotherapy side effects |
| spellingShingle | Anam A. Mazharuddin Andrew T. Whyte Dan S. Gombos Nimisha Patel Azadeh Razmandi Amina L. Chaudhry Nagham S. Al-Zubidi Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center Journal of Immunotherapy and Precision Oncology immune checkpoint inhibitors ocular immune-related adverse events nivolumab ocular toxicity immunotherapy side effects |
| title | Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center |
| title_full | Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center |
| title_fullStr | Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center |
| title_full_unstemmed | Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center |
| title_short | Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center |
| title_sort | highlights on ocular toxicity of immune checkpoint inhibitors at a us tertiary cancer center |
| topic | immune checkpoint inhibitors ocular immune-related adverse events nivolumab ocular toxicity immunotherapy side effects |
| url | https://theijpt.org/doi/pdf/10.36401/JIPO-22-14 |
| work_keys_str_mv | AT anamamazharuddin highlightsonoculartoxicityofimmunecheckpointinhibitorsataustertiarycancercenter AT andrewtwhyte highlightsonoculartoxicityofimmunecheckpointinhibitorsataustertiarycancercenter AT dansgombos highlightsonoculartoxicityofimmunecheckpointinhibitorsataustertiarycancercenter AT nimishapatel highlightsonoculartoxicityofimmunecheckpointinhibitorsataustertiarycancercenter AT azadehrazmandi highlightsonoculartoxicityofimmunecheckpointinhibitorsataustertiarycancercenter AT aminalchaudhry highlightsonoculartoxicityofimmunecheckpointinhibitorsataustertiarycancercenter AT naghamsalzubidi highlightsonoculartoxicityofimmunecheckpointinhibitorsataustertiarycancercenter |